Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthma

• Published in: Respiratory medicine Vol. 94; no. 7; pp. 724 - 732
• Main Authors: LUNDBÄCK, B., JENKINS, C., PRICE, M.J., THWAITES, R.M.A.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.07.2000; Elsevier
• Subjects: asthma; Biological and medical sciences; budesonide; cost-effectiveness analysis; Medical sciences; Pharmacology. Drug treatments; Respiratory system; salmeterol/fluticasone propionate; budesonide; salmeterol/fluticasone propionate; asthma; cost-effectiveness analysis; Human; Budesonide; Corticosteroid; Agonist; Costs; Respiratory disease; Bronchodilator; Treatment efficiency; Antiinflammatory agent; Salmeterol; β2-Adrenergic receptor; β-Adrenergic receptor agonist; Fluticasone; Antiasthma agent; Asthma; Chemotherapy; Treatment; Health economy; Adolescent; Adult; Combined treatment; Obstructive pulmonary disease; Public health; Comparative study

Despite a good understanding of the disease and its treatments, asthma continues to place a large economic burden on healthcare systems. As such, it is important to consider the economic impact of alternative therapeutic options for the treatment of this condition to ensure that scarce resources are...